China Resource Biopharma

China Resources Biopharmaceutical is a core subsidiary of China Resources Pharmaceutical Group, focusing on the research, development, and commercialization of high-end biologics. The company maintains a strong market presence in China with a portfolio of established recombinant protein products, including Reteplase for acute myocardial infarction and Epoetin alfa for anemia. CR Biopharma operates integrated R&D and manufacturing platforms across Shenzhen and Beijing, specializing in mammalian cell expression and microbial fermentation. Its clinical pipeline is heavily weighted toward biosimilars and innovative monoclonal antibodies in oncology and immunology. As part of a major state-owned conglomerate, the company leverages extensive distribution networks to provide affordable biological therapies to the Chinese market.